Bolt Biotherapeutics, Inc.

Listed Company

BOLTCIK 0001641281NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$7.70M

Net Income

$-33.38M

Total Assets

$56.75M

Equity

$26.50M

Shares Out

1.92M

Op. Cash Flow

$-39.85M

BOLT$4.23−25.27% · past yearDBEQ Basic

Daily closing prices

Business

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology therapies leveraging myeloid biology expertise. The company's proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate innate immune responses against cancer. The lead program, BDC-4182, targets claudin 18.2 in gastric and gastroesophageal junction cancers and is in Phase 1 development; additional pipeline programs include CEA ISAC, PD-L1 ISAC, and dectin-2 agonist antibody BDC-3042. The company collaborates with strategic partners including Genmab and Toray to expand its ISAC platform and maintains an exclusive license to foundational technology from Stanford University.

Summary from 10-K filed 2026-03-12

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	8	8	8	6	1
Research and development	29	57	62	73	76
General and administrative	14	18	23	23	18
Restructuring charges	1	3	0	—	—
Impairment charges	0	1	0	—	—
Total operating expense	44	81	84	96	94
Loss from operations	−36	−73	−76	−90	−93
Interest income, net	2	5	7	2	281,000
Other income, net	241,000	5	0	—	—
Total other income, net	3	10	7	2	−6
Net loss	−33	−63	−69	−88	−99
Net unrealized (loss) gain on marketable securities	−118,000	60,000	956,000	−600,000	−300,000
Comprehensive loss	−33	−63	−68	−89	−99
Net loss per share, basic	−17.85	−33.06	−1.83	−2.36	−2.97
Net loss per share, diluted	−17.85	−33.06	−1.83	−2.36	−2.97
Weighted-average shares outstanding, basic	2	2	38	37	33
Weighted-average shares outstanding, diluted	2	2	38	37	33

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	12	7	11	9	27
Short-term investments	16	40	91	160	159
Restricted cash	200,000	784,000	0	—	—
Prepaid expenses and other current assets	3	3	4	4	3
Total current assets	30	51	106	173	189
Property and equipment, net	1	3	5	6	6
Operating lease right-of-use assets	19	22	19	22	24
Restricted cash, non-current	2	981,000	2	2	2
Long-term investments	4	23	26	24	85
Other assets	138,000	62,000	2	1	1
Total assets	57	100	160	228	308
Accounts payable	1	2	3	4	4
Accrued expenses and other current liabilities	4	9	12	15	12
Deferred revenue	449,000	3	2	2	3
Operating lease liabilities	3	2	3	2	3
Total current liabilities	8	16	20	23	21
Operating lease liabilities, net of current portion	20	23	17	20	22
Deferred revenue, non-current	2	4	9	13	14
Other long-term liabilities	132,000	0	43,000	42,000	210,000
Total liabilities	30	42	47	56	58
Commitments and contingencies (Note 6)	—	—	—	—	—
Common stock, $0.00001 par value; 200,000,000 shares authorized at December 31, 2025 and 2024; 1,920,566 and 1,916,943 shares issued and outstanding at December 31, 2025 and 2024, respectively	0	0	0	0	0
Additional paid-in capital	487	485	477	468	457
Accumulated other comprehensive gain	−21,000	97,000	37,000	−919,000	−321,000
Accumulated deficit	−461	−427	−364	−295	−207
Total stockholders' equity	27	57	113	172	250
Total liabilities and stockholders' equity	57	100	160	228	308

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−33	−63	−69	−88	−99
Depreciation and amortization	1	2	2	2	1
Stock-based compensation expense	3	7	9	10	9
Accretion of discount on marketable securities	−670,000	−3	−4	184,000	3
Gain on sale of fixed assets	−288,000	−70,000	0	—	—
Non-cash lease expense	3	2	3	3	2
Prepaid expenses and other assets	76,000	3	−454,000	−903,000	−568,000
Accounts payable and accrued expenses	−5	−5	−3	3	7
Operating lease liabilities, net	−2	−1	−2	−3	−1
Deferred revenue	−5	−5	−4	−2	16
Other long-term liabilities	132,000	−43,000	1,000	−164,000	4,000
Net cash used in operating activities	−40	−61	−70	−77	−57
Purchase of property and equipment	−72,000	−41,000	−206,000	−2	−2
Proceeds from sales of property and equipment	963,000	148,000	0	—	—
Purchases of marketable securities	−29	−89	−165	−181	−313
Maturities of marketable securities	72	146	236	241	84
Net cash provided by investing activities	44	58	71	58	−232
Proceeds from issuance of common stock	19,000	108,000	253,000	503,000	1
Net cash provided by financing activities	19,000	108,000	253,000	503,000	311
NET INCREASE (DECREASE) IN CASH	4	−4	2	−18	22
Right of use assets obtained in exchange for operating lease obligations	0	6	0	852,000	15

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Bolt Biotherapeutics, Inc.'s CIK number?

Bolt Biotherapeutics, Inc.'s SEC CIK number is 0001641281 (1641281). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Bolt Biotherapeutics, Inc.'s SEC filings?

All of Bolt Biotherapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Bolt Biotherapeutics, Inc. last report earnings?

Bolt Biotherapeutics, Inc. (BOLT) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219361). This is Bolt Biotherapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Bolt Biotherapeutics, Inc.'s most recent earnings 8-K?

Bolt Biotherapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219361. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Bolt Biotherapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →